FLAGSHIP 1
CANCER & INFLAMMATION
FLAGSHIP LEADERS
RESEARCH FELLOW
Find Dr Hudson on ResearchGate
Dr Amanda Hudson ( current )
Dr Kelly McKelvey ( former )
A / Prof Viive Howell
Dr Connie Diakos
GOAL
TO INCREASE UNDERSTANDING OF THE RELATIONSHIPS BETWEEN INFLAMMATION , CANCER DEVELOPMENT AND TREATMENT RESPONSES . HARNESSING THIS FOR BETTER ANTI - CANCER BENEFIT .
DIRECTION TO
USE OF INFLAMMATION TO IMPROVE TREATMENT STRATEGIES AND OUTCOMES FOR CANCER PATIENTS . OUR UNDERSTANDING
Inflammation a cardinal feature of malignancy , contributing to the development of cancer , as well as being a consequence of the disease and its treatments . In established cancers , patients with evidence of systemic inflammation have demonstrated poorer outcomes and poorer response to treatment , with inferior anti - cancer effect and greater toxicities . is now recognised as Local inflammation , i . e . that arising within the primary tumour , has positive prognostic outcomes , however , as the recruitment of immune and inflammatory cells into the tumour signify a heightened immune response
to the malignancy , resulting in a positive anti - cancer benefit and lower systemic inflammation .
Systemic vs local inflammation Prognostic and predictive biomarkers Amelioration of inflammation to improve patient outcomes Treatment - related inflammation , in - cluding harnessing this for better anti - cancer benefit In this flagship , we aim to examine the following aspects of cancer - related inflammation :
P A G E
1 1
Made with FlippingBook - professional solution for displaying marketing and sales documents online